Modella AI’s Generative AI Co-Pilot PathChat DX Earns Breakthrough Status

Modella AI, a company focused on generative and agentic artificial intelligence (AI) for biomedicine, has been granted breakthrough status for its PathChat DX generative AI co-pilot.

PatchChat integrates advanced generative AI and multimodal analysis to help pathologists diagnose complex cases with better accuracy and efficiency, the company said. It uses a combination of pathology foundation models pretrained on extensive histology and image-text datasets, as well as a custom trained multimodal large language model (MLLM) to analyze high-resolution pathology images and clinical data.

Alexander Lazar MD, Ph.D., a professor and surgical pathologist at The University of Texas MD Anderson Cancer Center and scientific advisor to Modella AI said PathChat DX represents a transformative step for pathologists at every stage of their career.

By enhancing diagnostic precision and potentially accelerating the time to diagnosis, it addresses critical needs in patient care, where timely and accurate decisions directly impact treatment outcomes,” Dr. Lazar told the press. “With the rising demands and challenges in pathology, including growing workloads and burnout, tools like PathChat DX offer an opportunity to help pathologists improve both their efficiency and resilience in our complex field.”

PathChat DX is an extension of the PathChat model recently published in Nature and developed in the Mahmood Lab, led by Faisal Mahmood, Ph.D. at Mass General Brigham. It will now benefit from prioritized FDA review and increased collaboration with the agency, expediting the development and commercialization process.

“The Breakthrough Device Designation is a testament to the transformative potential of PathChat DX as one of the first generative AI tools specifically trained for human pathology,” said Dr. Jill Stefanelli, CEO of Modella AI. “This milestone brings us closer to our mission of using generative and agentic AI to accelerate diagnostic workflows.”

Artificial intelligence and machine learning promise to transform healthcare delivery, but there are still limits to its capabilities. For now.